FDA
-
-
-
-
-
-
-
Aditxt subsidiary Adimune plans FDA trials for autoimmune treatments
-
-
-
-
-
-
-
Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting
-
-
-
-
-
-
-
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs o
-
-
-
-
-
-
-
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
-
-
-
-
-
-
-
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
-
-
-
-
-
-
-
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
-
-
-
-
-
-
-
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

